Stockreport

How Rigel Pharmaceuticals' R289 Trial Progress and FDA Designations Will Impact RIGL Investors [Yahoo! Finance]

Rigel Pharmaceuticals, Inc.  (RIGL) 
Last rigel pharmaceuticals, inc. earnings: 2/27 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.rigel.com
PDF of R289 in relapsed or refractory lower-risk myelodysplastic syndrome (MDS), with up to 40 patients to be randomized to two dosing regimens. The advancement of R289 is [Read more]